Cancer and New Drugs · global
China’s New Cancer Drug Challenges Keytruda: Beyond Survival Data, Global Validation Awaits
Ivonescimab, developed by Akeso, extended overall survival in a Chinese lung cancer trial, becoming a striking example of China–U.S. biotech competition. But international partnerships, different patient populations, and regulatory review will determine how far this achievement can go.
An antibody developed in China is opening up new possibilities in the global competition among cancer drugs. In a direct comparison with Merck’s Keytruda, ivonescimab delivered results showing longer overall survival in a specific group of patients with lung cancer. The Economic Times recently used this development to examine China–U.S. biotech competition. For patients, the more practical questions are: To whom does this advantage apply, and can it be validated in other regions?
Developed by Akeso, ivonescimab is a bispecific antibody that targets both PD-1 and VEGF. The former is involved in signals that suppress immune cells, while the latter is associated with tumor blood vessel formation. This design combines releasing the immune brakes and inhibiting blood vessel formation in a single molecule. By comparison, pembrolizumab, the active ingredient in Keytruda, primarily blocks PD-1.
The key evidence supporting this challenge comes from the phase III HARMONi-2 trial. The study enrolled 398 previously untreated patients in China with locally advanced or metastatic non-small cell lung cancer whose tumors expressed PD-L1 and who had no EGFR or ALK alterations. A prespecified interim overall survival analysis presented at the World Conference on Lung Cancer in September showed median overall survival of 30.8 months in the ivonescimab group and 22.6 months in the pembrolizumab group. The hazard ratio for death was 0.73, with a 95% confidence interval of 0.57 to 0.95, reaching statistical significance.
This adds weight to the earlier efficacy signal. According to a summary in The ASCO Post, the trial had previously shown median progression-free survival of 11.1 and 5.8 months in the two groups, respectively. China also approved ivonescimab for these patients in April 2025. However, longer survival does not mean a better safety profile across the board: serious treatment-related adverse events occurred in 29.9% and 21.6% of patients in the two groups, respectively, while permanent discontinuation due to treatment-related adverse events occurred in 4.1% and 5.0%.
Moving from clinical results in China to overseas markets still involves different evidentiary thresholds. According to a September announcement by overseas partner Summit Therapeutics, ivonescimab remains investigational in its licensed territories, including the United States and Europe. The target review date for its U.S. FDA application is November 14, 2026. This application is based on a separate trial, HARMONi, rather than HARMONi-2, which directly compared the drug with Keytruda.
The two trials should not be conflated. HARMONi studied patients whose disease had progressed after treatment with third-generation EGFR-targeted drugs, comparing ivonescimab plus chemotherapy with placebo plus chemotherapy. Its primary overall survival analysis did not reach statistical significance, while subsequent follow-up yielded more favorable results. These data from multiple regions add to the drug’s clinical profile, but they do not directly establish that the advantage observed in China in HARMONi-2 has been reproduced globally in the same treatment setting.
Ivonescimab is therefore both a concrete example of China’s drug development capabilities and an illustration of the partnerships behind industry competition: a Chinese company designs the molecule, while a U.S. partner advances overseas development and regulatory submissions. A single trial is not enough to determine which country has gained a biotech advantage. What will truly change the treatment landscape is reproducible clinical benefit, acceptable safety, and regulators’ assessments of the complete evidence in each region.